Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Mural Oncology plc

Get SEC filing alerts via email and in your feed for Mural Oncology plc

MURA

Mural Oncology plc

About Mural Oncology plc

Mural Oncology plc is an Irish clinical-stage biotech focused on developing immunotherapies for cancer. Its core portfolio includes cytokine-based treatments like nemvaleukin alfa, designed to activate immune cells while minimizing toxicity. The company targets difficult-to-treat tumors such as mucosal melanoma and platinum-resistant ovarian cancer, leveraging protein engineering to optimize immune modulation. Its therapies aim to improve patient outcomes through innovative, targeted immuno-oncology solutions.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Mural Oncology plc

1
1
Mural Oncology plc Mural Oncology Reports $3.7 Million Net Loss and Significant Organizational Changes

Via official filing (AI summary) | 8 months ago | 0 comments

2
1
Mural Oncology plc Mural Oncology Reports $47.98 Million Net Loss and Restructuring Challenges in Latest Quarter

Via official filing (AI summary) | 11 months ago | 0 comments

3
1
Mural Oncology plc Mural Oncology Reports $33.1 Million Net Loss and Discontinues Lead Product Development

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Mural Oncology plc Mural Oncology Reports $128.5 Million Net Loss for 2024, Decreased R&D Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments

5
1
Mural Oncology plc Mural Oncology Reports Financial Results, Anticipates Continued Losses Amid Clinical Development Efforts

Via official filing (AI summary) | over 1 year ago | 0 comments